Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

OXURION to Participate in Upcoming Investor Meetings

8 Mar 2021

Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in diabetic eye disease, today announces its management will participate and meet with investors at the following upcoming virtual meetings in March: 

  • H.C. Wainwright Global Life Sciences Conference - March 9-10, 2021

Pre-Recorded Company Presentation, featuring Tom Graney, CFA, CFO to be made live on March 9 at 7:00 am EST. Follow this link to the webcast. A replay will be available for approximately 90 days following the conference.

  • 14th Annual European Life Sciences CEO Forum - March 10-11, 2021

Pre-Recorded Company Presentation, featuring Patrik De Haes, MD, CEO available on demand for all registered users to view on events portal.

  • 33rd Annual Roth Conference - March 15-17, 2021

Oxurion to join panel discussion entitled ‘Disruptive Back of the Eye Therapies’ which will take place on March 16 at 9:00 am EST.

Press release attachment: 
Investors; Company